Rare disease biotech Edgewise Therapeutics files for a $100 million IPO
By: Colorado BioScience Association Date: 03/09/2021
Edgewise Therapeutics, a Phase 1 biotech developing small molecule therapies for rare muscle disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Edgewise is focused on the discovery, development, and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its lead candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies. It is currently in a Phase 1 trial for Duchenne muscular dystrophy, Becker muscular dystrophy, and Limb-girdle muscular dystrophy.
The Boulder, CO-based company was founded in 2017 and plans to list on the Nasdaq under the symbol EWTX. Edgewise Therapeutics filed confidentially on December 18, 2020. J.P. Morgan, Goldman Sachs and SVB Leerink are the joint bookrunners on the deal. No pricing terms were disclosed.
Find out more in the Nasdaq press release.